MBRX Moleculin Biotech
- 2.5200
- -0.2700-9.68%
- 2.5500
- +0.0300+1.19%
Moleculin Biotech News
Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $20
Buy Rating for Moleculin Biotech on Promising Annamycin Trials and Undervalued Shares
Analysts' Top Healthcare Picks: Moleculin Biotech (MBRX), MiNK Therapeutics (INKT)
Moleculin Biotech Analyst Ratings
Maxim Adjusts Price Target on Moleculin Biotech to $20 From $45, Maintains Buy Rating
Moleculin Biotech Analyst Ratings
HC Wainwright & Co. Initiates Coverage On Moleculin Biotech With Buy Rating, Announces Price Target of $3
Moleculin Biotech Analyst Ratings
Oppenheimer Keeps Their Buy Rating on Moleculin Biotech (MBRX)
Analysts' Top Healthcare Picks: Moleculin Biotech (MBRX), Vir Biotechnology (VIR)
Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (SRRK) and Moleculin Biotech (MBRX)
Maxim Group Reaffirms Their Buy Rating on Moleculin Biotech (MBRX)
Analysts Offer Insights on Healthcare Companies: Intra-Cellular Therapies (ITCI), Phibro Animal Health (PAHC) and Moleculin Biotech (MBRX)
Roth MKM Maintains Buy on Moleculin Biotech, Maintains $16 Price Target
Analysts' Top Healthcare Picks: Moleculin Biotech (MBRX), Biomea Fusion (BMEA)
Maxim Group Sticks to Its Buy Rating for Moleculin Biotech (MBRX)
Oppenheimer Reiterates Outperform on Moleculin Biotech, Maintains $5 Price Target
Roth MKM Sticks to Their Buy Rating for Moleculin Biotech (MBRX)
Analysts Offer Insights on Healthcare Companies: Moleculin Biotech (MBRX) and Valneva (VALN)
Analysts Conflicted on These Healthcare Names: Achilles Therapeutics (ACHL), Cidara Therapeutics (CDTX) and Moleculin Biotech (MBRX)
Analysis
Price Target
No Data
No Data